Nihon Kohden Of Japan To Distribute Cyberonics Device If Approved
This article was originally published in PharmAsia News
Executive SummaryJapan's Nihon Kohden has agreed with U.S.-based Cyberonics to distribute the Houston company's VNS Therapy Systems in Japan. The deal is subject to approval of the implanted device for vagus nerve stimulation by Japanese authorities. The U.S. FDA already has approved VNS for treating refractory epilepsy and depression resistant to other treatments. Cyberonics began distributing VNS in China last year. (Click here for more
You may also be interested in...
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.